Human Health. 1. Enhancing public health program planning and coordination through strengthening the institutional capacity of the MOH to command and control in a coordinated fashion with the MARA the implementation of the National Pandemic Influenza Action Plan and support the National Committee for the Control of Zoonotic Diseases to provide coordination among relevant ministries and agencies.
Human Health. The Parties shall establish action levels to protect human health based on multimedia exposure and the interactive effects of toxic substances.
Human Health. The human health risk assessment (HHRA) will rely on analytical results associated with Phase I soil, groundwater, surface water, and soil gas samples, as well as historical groundwater and soil samples collected at the site. This section focuses on the Phase I samples of specific relevance to characterizing potential human health exposures both on and off site. These samples are associated with four investigations identified under Task 3 (Field Investigation/Data Acquisition) in the RI/FS work plan. Discussed below is the HHRA-related sampling conducted as part of each of these investigations: geological and storm sewer investigations (Section 4.9.1); hydrogeologic investigations (Section 4.9.2); surface water investigation (Section 4.9.3); and sub-slab vapor monitoring investigation (Section 4.9.4).
Human Health. 6.1 Introduction 1
Human Health. As mentioned above, this is the area with the highest participation level and where the countries and the IAEA have invested the greatest share of resources under ARCAL since 1989. Details on the more important accomplishments are given below.
Human Health. There are generally more cases of malaria in PUAs compared to other urban areas of Lusaka. This is mainly due to poor sanitary and environmental conditions. Limited access to health services contrib- utes to severity of any disease as in-time treatment is often not available. Waterborne diseases such as diarrhoea, cholera and dysentery are quite common in PUAs and the project locations. HIV/AIDS prevalence is a major problem in Zambia. The overall HIV prevalence among all women and men age 15-49 tested in the 2013-14 ZDHS was 13% (CSO et al. 2015). Latest figures (CSO et al. 2015) reported HIV/AIDS cases in Lusaka Province to be 16.3%, with 19.4% positive women and 13% HIV positive men. Specific data on water borne diseases occurring in the neighbourhood of the current WWTP systems do not exist. However, residents reported that malaria and diarrhoea are most common in their communities. Some households use water from shallow xxxxx and boreholes for drinking purposes, likely to be contaminated by unsealed excreta pits. In Xxxxxx Xxxxxx Compound neighbouring the Ngwerere ponds residents suspect that the wastewater from ponds is infiltrating into their groundwa- ter. In general, the incidence of malaria has declined at district level since 2003 due to indoor residual spraying programme and other anti-malarial interventions that have been introduced such as the use of treated mosquito nets.
Human Health. 1. Provision of technical assistance for enhancing public health program planning and coordination, through: (a) strengthening command and coordination mechanisms within the health sector; (b) revising the Ministry of Health’s contingency plan; (c) preparing a detailed plan defining operational priorities and identifying roles and responsibilities at each level of the health system; and (d) developing an implementation plan for “social distancing” and “hospital clean-out” measures in the case of an epidemic.
Human Health. The royalty rates and milestone payments set forth above shall apply to Products for the treatment of animal bacterial diseases only. If Pfizer chooses to develop a Licensed Product for the treatment of diseases in humans, the parties agree that the royalty rates and milestones set forth in the License and Royalty Agreement between the parties to this Agreement for human health Products, dated March 1, 1996, shall apply to such Products.
Human Health. Section 1.8 to the contrary notwithstanding, Pfizer shall have the right to develop Products that can be used for the treatment of bacterial diseases in humans. If Pfizer decides to develop a Product for use in humans, the terms and conditions of the License and Royalty Agreement between the parties to this Agreement, dated March 1, 1996, shall apply.
Human Health a. Will the proposal result in exposure of people to potential health hazards?
